For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

and Tremfya (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to ...

After hours: 28 February at 7:58:44 pm GMT-5 ...

Severe cases may require treatment with powerful psoriasis medications, including: Trexall (methotrexate) Sandimmune (cyclosporine) Biologic drugs, including Enbrel (etanercept), Remicade (infliximab) ...

A 175% increase in human papilloma virus vaccination initiation was observed following the implementation of an office based, same-day vaccine program in a dermatology clinic. Vaccination rates for ...

The National Rosacea Society has opened its applications for research funding as the grant program celebrates its 25th anniversary, according to a press release.